MELA Sciences Wins at NYC Ceremony for its Flagship Product, MelaFind; Awards Celebrate 25 Years of Honoring Innovators and Innovation

IRVINGTON, NY, April 27, 2012 -- MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that has developed MelaFind^®, announced today that it was named a bronze Edison Award winner for MelaFind,  a non-invasive, objective, multi-spectral computer vision system to provide additional information to dermatologists for a decision to biopsy. The Edison Awards™ celebrates 25 years of honoring the best in innovation and excellence in the development of new products and services.

At the sold-out April 26 event in New York City, Dr. Joseph Gulfo, President and CEO of MELA Sciences, joined hundreds of senior executives from some of the world’s most recognized companies to acknowledge the hard work and commitment of all of the 2012 Edison Award winners. 

"We are thrilled that MelaFind, which is a first-of-its kind device, was recognized by the Edison Awards for its innovative excellence," said Dr. Gulfo. "The detection of melanoma at its most curable stages can result in decades of high-quality life saved, versus the treatment of this terrible disease at late stages, which offers several months of life extension, at best. In providing more information to dermatologists, MelaFind allows for more informed decisions when making difficult biopsy decisions in an effort to detect the disease at its earliest, most curable stages."

Being recognized with an Edison Award has become one of the highest accolades a company can receive in the name of innovation and business. The awards are named after Thomas Alva Edison (1847-1931) whose inventions, new product development methods and innovative achievements literally changed the world, garnered him 1,093 US patents and made him a household name around the world. 

"As the pace of innovation quickens and the ‘race to next’ becomes ever more competitive, it’s increasingly important to take a moment out of our hectic lives to recognize excellence in innovation and greatness in the teams of innovators who make our future. We are honored to present MELA Sciences with an Edison Award as one of the leading innovators of today and tomorrow," says Thomas Stat, 2012 Edison Awards Steering Committee Chairman.

The ballot of nominees for the Edison Awards was judged by a panel of more than 3,000 leading business executives including past award winners, members of the Marketing Executives Networking Group (MENG), academics and leaders in the fields of product development, design, engineering, science and medical.  

This year, in a comprehensive, peer-review process, the nominees were judged on a new set of evaluation criteria developed in partnership with Nielsen. The new criteria establishes a new definition of innovation, leveraging the primary assessment themes of Concept, Value, Delivery and Impact. 

About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind^®, and its further design and development.  MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion’s level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

About the Edison Awards
The Edison Awards represent the spirit of innovation personified by Thomas Edison, inspiring America’s drive to remain in the forefront of creativity and ingenuity in the global economy.  Sponsors of the 2012 Edison Awards include:  Nielsen, USA TODAY, Discovery Communications, SCIENCE, CSRware, applepeak and ViridiSTOR. 

For more information about the Edison Awards and a full list of winners, visit www.edisonawards.com. 

For further information contact:

For Investors
Lynn Pieper
Westwicke Partners
415-202-5678

IRVINGTON, NY, April 24, 2012 -- MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that has developed MelaFind^®, today announced that Joseph V. Gulfo, MD, President and CEO, will be presenting at the 37th Annual Deutsche Bank Health Care Conference in Boston, MA on Tuesday, May 8, 2012.

To access a live webcast of this presentation, visit the investor relations section of www.melasciences.com. A replay will be available on the company's website for two weeks following the presentation.

About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind^®, and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes," "predicts" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties facing the company such as those set forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission (the "SEC"). Factors that might cause such a difference include whether Melafind(R) achieves market acceptance or becomes commercially viable. Given the uncertainties affecting companies in the medical device industry such as the Company, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. The Company urges you to carefully review and consider the disclosures found in its filings with the SEC which are available at www.sec.gov and www.melasciences.com.

For further information contact:

For Investors
Lynn Pieper
Westwicke Partners
415-202-5678

For Media
Melissa Hurley
Ricochet Public Relations
212-679-3300 x128

IRVINGTON, NY, April 23, 2012 -- MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that has developed MelaFind®, today announced that it will host a meeting for investors and analysts on Monday, May 7, 2012, 10–11 AM ET in New York City.

Joseph V. Gulfo, MD, MELA Sciences President and CEO, will host the meeting and provide a brief introduction and business update. He will then moderate a panel discussion and presentations from leading dermatologists. The clinicians will discuss their current practice patterns, the clinical utility of MelaFind and how they are incorporating it into their practice as well as the product’s potential market opportunity. Following the presentations, there will be a question and answer session.

Space is limited, those interested in attending should RSVP to Lynn Pieper at lynn.pieper@westwicke.com.

A live audio webcast and slides of the MELA Sciences Investor Meeting will be accessible through the investor relations section of the Company’s website at www.melasciences.com. An archived edition of the presentation will be available later that day and will be available for at least 90 days afterwards.

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind®, and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion’s level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

For further information contact:

For Investors Lynn Pieper Westwicke Partners 415-202-5678

For Media Melissa Hurley Ricochet Public Relations 212-679-3300 x128

MELA Sciences to Release First Quarter Financial Results and Host Conference Call on Thursday, May 3, 2012

IRVINGTON, NY, April 16, 2012 -- MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that has developed MelaFind^®, today announced that it will release its 2012 first quarter financial results after the close of trading on Thursday, May 3, 2012. MELA Sciences executives will also host a conference call that day at 4:30 PM ET to discuss the results, as well as provide a general business update.

Date: Thursday, May 3, 2012 Time: 4:30 PM ET

To participate in the teleconference, please dial: Domestic toll-free: (888) 437-9481 International: (719) 325-2337 Participant Code: 5102483

To listen via live webcast, please go to the investor relations section of the MELA Sciences website at http://www.melasciences.com approximately 10 minutes prior to the teleconference start time. If you are unable to participate during the live conference call and webcast, the conference call audio cast will be archived and available for replay for approximately 90 days.

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind^®, and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, visit www.melasciences.com.

For further information contact:

For Investors Lynn Pieper Westwicke Partners 415-202-5678

For Media Melissa Hurley Ricochet Public Relations 212-679-3300 x128